Neurodegenerative diseases (NDD) are a major global public health concern and a leading cause of disability-adjusted life-years, moreover, therapeutic options are limited. Brain targeting has always been challenging due to the presence of various physiological barriers, of which one of the most robust barriers is Blood Brain Barrier (BBB). The BBB consists of endothelial cells which are the tight layers surrounded by astrocyte foot processes, and these anatomic features together constitute a significant barrier that hampers the delivery of drugs to the central nervous system (CNS). In the past few decades, the nose-to-brain targeted delivery has received a great deal of attention because of factors like the rapid onset of action, increased bioavailability, manageable surface area and avoids the first-pass metabolism, thus considering it as a non-invasive, convenient and reliable approach that may overcome the challenges associated with nose-to-brain targeted delivery. However, this strategy still possesses significant limitations, which led to the development of nanotechnological approaches like solid lipid nanoparticles, polymeric nanoparticles, nanoemulsions, liposomes and polymeric micelles, thus circumventing these barriers. The present review article highlights a complete understanding of every aspect related to nose-to-brain delivery: mechanism involved in the transport of drugs from nose-to-brain via BBB by complex pathways, strategies to overcome the barrier-BBB, recent examples, and applications of nose-to-brain targeted delivery using nanotechnologies for brain gliomas and other neurological disorders.